Helps to maintain healthy blood glucose levels through Herbs.
|
|
Clinical Evaluation of Fenugreek Seed Extract in 2 58 Patients with Type- 2 Diabetes : An Add-On Study at Two Medical Colleges in India.
Efficacy Conclusions
- A significant decrease in HbA1c levels was observed as compared to respective baseline value and as compared to placebo after weeks.
- Fenfuro caused significant reduction in the fasting blood sugar levels.
- Fenfuro caused significant reduction in the post prandial (PP) blood sugar levels as compared to Placebo group as well as compared to respective baseline value.
- 83% of the patients reported decrease in fasting sugar levels in Fenfuro treated group as compared to 62% in Placebo treated group.
- 89% of the patients reported decrease in PP sugar levels in Fenfuro treated group as compared to 72% of the patients in the Placebo treated group.
- 48.8% of the patients reported reduced dosage of anti diabetic therapy in Fenfuro treated group, where as 18.05% of the patients reported reduced dosage of anti diabetic therapy in Placebo treated group.
- Fasting glucose: The mean fasting glucose levels were significantly decreased in FENFURO-treated patients, whereas these levels increased in on-going anti-diabetic therapy-treated patients. FENFURO caused 38.26% decrease in fasting glucose levels on completion of the treatment. Such decrease in fasting glucose levels was observed in 95.2% of the study population on completion of the treatment with FENFURO.
- Post-prandial (PP) glucose: FENFURO caused significant decrease in PP glucose levels on completion of the treatment as compared to the on-going anti-diabetic therapy-treated population. The decrease in mean PP glucose levels were up to 44.04% in the FENFURO-treated study population on completion of the treatment. As observed on completion of the treatment with FENFURO, 88.10% of study population shown to have decrease in PP glucose levels.
- Glycated hemoglobin (HbA1c): FENFURO treatment resulted in normalizing the mean HbA1c levels of the study population. The HbA1c levels decreased significantly in the study population of both groups on completion of the treatment. Mean HbA1c levels decreased up to 34.70% in
- FENFURO-treated group whereas on-going anti- diabetic therapy caused 21.51% decrease in HbA1c levels. These HbA1c levels came to normal range (Good control range – 4.5-6.3%) in FENFURO-treated study population whereas they were still abnormal (Poor control levels – 7.6%) in on-going anti-diabetic therapy treated population till 12 weeks of treatment.
Safety Conclusions
- No significant change in serum SGOT, SGPT & ALP activities was observed, indicating investigational product (Fenfuro-fenugreek seed extract) was safe for liver functioning.
- No significant change in blood urea nitrogen and creatinine levels was observed indicating investigational product (Fenfuro-fenugreek seed extract) was safe for kidney functioning.
- No significant change in hematological parameters was observed.
- Keeping hematological and biochemical results in view, investigational product was safe for consumption.
- No significant change in the liver function tests (serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, alkaline phosphates activities and serum bilirubin levels) was observed on completion of the treatment.
- No significant change in the serum urea levels and creatinine levels was observed on completion of the treatment.
- No significant change in the hematological parameters was observed on completion of the treatment.
Unique features of FENFUROTM
- FENFUROTM is a first of its kind product derived from single herb with proven results for maintaining blood sugar levels.
- Scientific Research supports the non-toxicity of the product.
- Scientifically processed without affecting the chemical properties of the active ingredient to give maximum benefit.
*Complete clinical data available on request
Innovative product FENFURO is now protected with following patents :
Mode Of Action
It is known that in a healthy human body each cell membrane normally contains some 20000 active insulin receptors whereas an insulin resistance patient’s cell membrane has around 5000 active insulin receptors, causing excess free-floating insulin and glucose.
Fenfuro is the first dual action insulin sensitizer and exhibits hypocholestremic activity.
In presence of high fiber Furostanolic saponin cells are more sensitive to insulin.
An increase in number of insulin receptor sites occurs which are responsive to insulin to stimulate the cells ability to burn glucose (i.e newer insulin receptors with definite insulin sensitizing activity due to specific effects on the islets of langerhans in the Pancreas)
High fiber Furostanolic saponins delay the rate of gastric emptying and slows carbohydrate absorption & thereby reducing insulin requirements. THEREBY BRINGING EUGLYCEMIC EFFECTS
Furostanolic saponins also increase peripheral utilization of insulin & THEREBY BRINGS DOWN THE HYPERINSULLINAMEA the root cause of DIABETIC COMPLICATIONS
High fiber Furostenolic saponin increases viscosity of the digesta thereby inhibiting cholesterol absorption from small intestine and also the inhibition of bile acid re-absorption from the terminal ileum. Thus there is decrease in VLDL, LDL & Triglycerides level where as no effects on HDL.
Recommended Dosage
TYPE-2 DIABETES:
PATIENTS ON OHA AND INSULIN – Add FENFURO™ to the existing medicinal regimen. Recommended dosage of FENFURO™ for better and fast results is one capsule three times a day (before meal). Patient should monitor FBS & PPBS level from 7th-9th day onwards. If hypoglycemic symptoms are noticed, insulin intake can be tapered depending upon level of FBS & PPBS in consultation with your physician.
FENFURO™ dosage of three capsules is to be continued till the time insulin is no longer required. After this two capsules of FENFURO™ (one in the morning and one in the evening before meal) have to be taken with other OHA till HbA1c <7%. Once HbA1c <7% is achieved, dosage of OHA to be adjusted in consultation with your physician.
PATIENTS TAKING MULTI MOLECULE OHA – Add FENFURO™ to existing medicinal regimen. Recommended dosage of FENFURO™ for better and fast results is one capsule twice a day (one in the morning and one in the evening before meal) till HbA1c <7%. Once HbA1c <7% is achieved, dosage of OHA is to be adjusted in consultation with your physician.
TYPE-1 DIABETES:
If C-peptide is very low, FENFURO™ can be added to the existing medicinal regimen for three months regularly. Recommended dosage of FENFURO™ is three times a day (with meal). Patient should monitor FBS & PPBS level from 7th-9th day onwards. If hypoglycemic symptoms are noticed insulin intake can be tapered depending upon level of FBS & PPBS in consultation with your physician. After three months if any improvement is noticed in C-peptide level, patient can continue taking FENFURO™ otherwise FENFURO™ can be withdrawn.
If C-peptide is normal, probably it is MODY (Maturity-onset diabetes of the young) case & FENFURO™ can help to regenerate newer insulin receptor sites & thereby insulin dosage can be reduced and diabetic complication can be controlled by reducing hyperinsulinemia. Recommended dosage of FENFURO™ is three times a day (with meal). Patient should monitor FBS & PPBS level from 7th-9th day onwards. If hypoglycemic symptoms are noticed insulin intake can be tapered depending upon level of FBS & PPBS in consultation with your physician.
Test Specification
Fasting Blood Sugar
This test shows how well your body uses sugar called glucose. It is a method for learning how much glucose (sugar) there is in a blood sample taken after an overnight fast. The fasting blood glucose test is commonly used in the detection of diabetes mellitus. A blood sample can be taken in a lab, doctor’s office, or hospital. The test is done in the morning before the person has eaten.
Two Hours PP Blood Sugar
2-hour postprandial blood sugar (glucose) test measures the blood sugar exactly 2 hours after eating a meal. Blood sugar tests may be used to check for diabetes and to see how treatment for diabetes is working. Normally, before age the 50, blood sugar levels should rise no higher than 140 milligrams per deciliter (mg/dL), 2 hours after eating a meal. Healthy adults increase their blood sugar levels by 10 mg/dL for every 10 years of life before the age of 50.
HbA1c Test
The A1C test is a common blood test used to diagnose Type 1 and Type 2 diabetes and then to gauge how well you’re managing your diabetes.The A1C test result reflects your average blood sugar level for the past two to three months. Specifically, the A1C test measures what percentage of your hemoglobin — a protein in red blood cells that carries oxygen — is coated with sugar (glycated). The higher your A1C level, the poorer your blood sugar control. And if you have previously been diagnosed with diabetes, the higher the A1C level, the higher your risk of diabetes complications.
C-peptide
A C-peptide test is a blood test which is carried out to find out how much insulin your body is producing. This may be useful for determining whether you have type 1 or type 2 diabetes or whether you have insulin resistance.
How is this test performed? To measure level of C-peptide a fasting blood test is taken. You will be asked not to eat or drink (certain fluids) for 8 to 12 hours before the test. If you take blood glucose lowering medication you will likely be asked to stop taking these in the run up to the test.
The normal range for a C-peptide test is: 0.51 to 2.72 nanograms per millilitre (ng/mL).
For the blood test itself, a sample of blood will be taken from your arm and it shouldn’t take much more than a minute. Levels of C-peptide as well as the blood glucose level will be measured.
Blood Pressure mm/hg
The doctor measures the maximum pressure (systolic) and the lowest pressure (diastolic) made by the beating of the heart.
— The systolic pressure is the maximum pressure in an artery at the moment when the heart is beating and pumping blood through the body.
— The diastolic pressure is the lowest pressure in an artery in the moments between beats when the heart is resting.
Both the systolic and diastolic pressure measurements are important – if either one is raised, it means you have high blood pressure (hypertension).
Total Cholestrol mg/dl
A total cholesterol test measures all the cholesterol in your blood. Cholesterol is a soft, wax-like substance found in all parts of the body. Your body needs a little bit of cholesterol to work properly. But too much cholesterol can clog your arteries and lead to heart disease. Some cholesterol is considered “good” and some is considered “bad.”
Different blood tests are needed to individually measure each type of cholesterol.
HDL
HDL stands for high-density lipoprotein. It’s also sometimes called “good” cholesterol. Lipoproteins are made of fat and protein. They carry cholesterol, triglycerides, and other fats, called lipids, in the blood from other parts of your body to your liver.
LDL
Cholesterol mg/dl – LDL stands for low-density lipoprotein. It’s also sometimes called “bad” cholesterol. Lipoproteins are made of fat and protein. They carry cholesterol, triglycerides, and other fats, called lipids, in the blood to various parts of the body. LDL carries cholesterol to various tissues throughout the body. Too much LDL, commonly called “bad cholesterol,” is linked to cardiovascular disease. The lower your LDL, the lower your risk for heart disease or stroke.
Triglycerides mg/dl
The triglyceride level is a laboratory test to measure the amount of triglycerides in your blood. Triglycerides are a type of fat. Your body makes some triglycerides. Triglycerides also come from the food you eat. When you eat, your body uses carbohydrate calories for immediate energy. Leftover calories are turned into triglycerides and stored in fat cells for later use. If you eat more calories than your body needs, your triglyceride level may be high.
Parameters | Good | Fair | Poor |
|---|---|---|---|
| Fasting Blood Sugar mg/dl | 70-110 | 111-125 | More than 125 |
| Two Hours PP Blood Sugar mg/dl | 120-140 | 141-200 | More than 200 |
| HbA1c | 6 | 7 | More than 7 |
| Blood Pressure mm/hg | Less than 130/80 | Less than 140/90 | More than 140/90 |
| Total Cholestrol mg/dl | Less than 200 | 200-240 | More than 240 |
| HDL-Cholestrol mg/dl | More than 45 | 35-45 | Less than 35 |
| LDL – Cholestrol mg/dl | Less than 100 | 100-129 | More than 130 |
| Triglycerides mg/dl | Less than 150 | 150-200 | More than 200 |
ABOUT DIABETES
Diabetes is a chronic, potentially debilitating and often fatal disease. The disease occurs as a result of problems with the production and supply of insulin in the body. Either the body produces no or insufficient insulin (type 1 diabetes), or the body cannot use the insulin it produces effectively (type 2 diabetes). Insulin is a hormone made by the pancreas that helps ‘sugar’ (glucose) to leave the blood and enter the cells of the body to be used as ‘fuel’.
There are two main types of diabetes:
Type 1
Diabetes is sometimes called insulin-dependent, immune-mediated or juvenile-onset diabetes. It is caused by an auto-immune reaction where the body’s defense system attacks the insulin-producing cells. The reason why this occurs is not fully understood. People with type 1 diabetes produce very little or no insulin. The disease can affect people of any age but usually occurs in children or young adults. People with this form of diabetes need injections of insulin every day in order to control the levels of glucose in their blood. If people with type 1 diabetes do not have access to insulin, it can lead to many complications and can be fatal as well.
Type 2
Diabetes is sometimes called non-insulin dependent diabetes or adult-onset diabetes. People with type 2 diabetes do not usually require injections of insulin. Usually, they can control the glucose in their blood by watching their diet, taking regular exercise, oral medication, and possibly insulin. Type 2 diabetes is most common in people older than 45 who are overweight. However, as a consequence of increased obesity among the young, it is becoming more common in children and young adults as well. Type 2 diabetes is the most common type of diabetes and accounts for 90-95% of all diabetes. If people with type 2 diabetes are not diagnosed and treated, they can develop serious complications, which can result in early death. being aware of it. Many others do not have access to adequate medical care. The onset of type 2 diabetes is also linked to genetic factors but obesity, physical inactivity, and unhealthy diet increase the risk of developing Type 2 diabetes.
Some women develop a third, usually temporary, type of diabetes called ‘Gestational Diabetes’ when they are pregnant. Gestational diabetes develops in 2-5% of all pregnancies and usually disappears when the pregnancy is over. Women who have had gestational diabetes are at an increased risk of developing type 2 diabetes later on in life.
Impaired Glucose Tolerance (IGT)
People with impaired glucose tolerance (IGT) have glucose levels that are above normal but below the level at which diabetes is diagnosed. People with IGT have a significant risk of developing type 2 diabetes. They are thus an important target group for primary prevention. Changes in lifestyle, including diet and physical activity, can greatly reduce the onset of diabetes.
Diabetes Complications
Over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves.
- Diabetes increases the risk of heart disease and stroke. 50% of people with diabetes die of cardiovascular diseases (primarily heart disease and stroke).
- Combined with reduced blood flow, neuropathy in the feet increases the chances of foot ulcers and eventual limb amputation.
- Diabetic retinopathy is an important cause of blindness, and occurs as a result of long-term accumulated damage to the small blood vessels in the retina. After 15 years of diabetes, approximately 2% of the people become blind, and about 10% develop severe visual impairment.
- Diabetes is among the leading causes of kidney failure. 10-20% of the people with diabetes die of kidney failure.
- Diabetic neuropathy is damage to the nerves as a result of diabetes, and affects up to 50% of the people with diabetes. Although many different problems can occur as a result of diabetic neuropathy, common symptoms are tingling, pain, numbness, or weakness in the feet and hands.
- The overall risk of dying among people with diabetes is at least double the risk of their peers without diabetes.
Diabetes Diagnosis
Diabetes is a preventable and controllable disease.
Preventing Type 2 Diabetes
People with prediabetes are at high risk of developing type 2 diabetes. Their blood glucose levels are higher than normal, but not high enough to be classified as diabetes.
Acc.to WHO, In 2014 the global prevalence of diabetes was estimated to be 9% among adults aged 18+ years. In 2012, an estimated 1.5 million deaths were directly caused by diabetes. More than 80% of diabetes deaths occur in low and middle-income countries. WHO projects that diabetes will be the 7th leading cause of death in 2030. Healthy diet, regular physical activity, maintaining normal body weight, and avoiding tobacco use can prevent or delay the onset of type 2 diabetes.
Controlling Diabetes
Disability and premature death are not inevitable consequences of diabetes. Physical activity and dietary interventions, self-management training, ongoing support, and, when necessary, medications can help control the effects of diabetes. By working with a support network and health care providers, a person with diabetes can prevent premature death and disability.
For example,
- Reducing A1c (a measure of blood glucose control) by one percentage point can reduce the risk of eye, kidney, and nerve diseases by 40%.
- Controlling blood pressure can reduce the risk of heart disease and stroke by 33%–50% and the risk of eye, kidney, and nerve diseases by 33%.
- Improving control of low-density lipoprotein (LDL) cholesterol can reduce cardiovascular complications by 20%–50%. Treating diabetic eye disease with laser therapy can reduce the risk of loss of eyesight by 50%–60%.
- Accessing comprehensive foot care programs can reduce amputation rates by 45%–85%.
Global Healthcare Expenditure
Estimated global healthcare expenditures to treat and prevent diabetes and its complications were at least US dollar (USD) 376 billion in 2010. By 2030, this number is projected to exceed USD 490 billion. Expressed in international dollars (ID), which is corrected for differences in purchasing power, global expenditures on diabetes were at least ID 418 billion in 2010, and at least ID 561 billion in 2030. An average of USD 703 (ID 878) per person was spent on diabetes in 2010 globally.
Expenditures spent on diabetes care are not evenly distributed across age and gender groups. More than three-quarters of the global expenditure in 2010 was used for persons who were between 50 and 80 years of age. Also, more money is expected to be spent on diabetes care for women than for men.
Disparities in healthcare spending
There is a large disparity in healthcare spending on diabetes between regions and countries. More than 80% of the estimated global expenditures on diabetes are made in the world’s economically richest countries, not in the low and middle-income countries where over 70% of people with diabetes live.
The United States of America projected to spend USD 198 billion or 52.7% of global expenditure in 2010, while India, the country with the largest population of people living with diabetes, spent an estimated USD 2.8 billion, or less than 1% of the global total. An estimated average of USD 7,383 per person with diabetes was spent on diabetes-related care in the USA but less than USD 10 per person was spent in Burundi and Myanmar in 2010.
The financial burden borne by people with diabetes and their families as a result of their disease depends on their economic status and the social insurance policies of their countries. Those living in low income countries pay a larger share of the expenditure because of poorer organized systems of medical care insurance and/or lack of public medical services. In Latin America, for instance, families pay 40-60% of medical care expenditures from their own pockets. In the poorest countries, people with diabetes and their families bear almost the whole cost of the medical care they cannot afford.
Impact on the economy
Diabetes imposes a large economic burden on the individual, national healthcare system and economy. Healthcare expenditures on diabetes were 11.6% of the total healthcare expenditure in the world in 2010. About 80% of the countries are predicted to spend between 5% and 13% of their total healthcare dollars on diabetes.
Besides excess healthcare expenditure, diabetes also imposes large economic burdens in the form of lost productivity and foregone economic growth. The American Diabetes Association estimated that the US economy lost USD 58 billion, equivalent to about half of the direct healthcare expenditure on diabetes in 2007, as a result of lost earnings due to lost workdays, restricted activity days, lower productivity at work, mortality and permanent disability caused by diabetes. Such losses are perhaps relatively larger in poorer countries because premature death due to diabetes occurs at much younger age. The world health organization (WHO) predicted net losses in national income from diabetes and cardiovascular disease of ID 557.7 billion in China, ID303.2 billion in the Russian federation, ID 236.6 billion in India, ID 49.2 billion in Brazil and ID 2.5 billion in Tanzania (2005 ID), between 2005 and 2015.
The largest economic burden, therefore, is the monetary value associated with disability and loss of life as a result of the disease itself and its related complications. This economic burden, however, can be reduced by implementing many inexpensive, easy to use interventions, most of which are cost-effetive or cost-saving, even in the poorest countries. Nonetheless, these interventions are not widely used in low and middle income countries.
FAQs
FENFUROTM, a proprietary phytochemical product (available in capsule form) is a group of Furostanolic Saponins derived from Trigonella Foenum Graecum by an innovative US patented process.
FENFUROTM helps to promote Healthy Glucose & Lipid Levels.
FENFUROTM is a standardized extract (with defined Active Ingredient) processed and derived from Fenugreek seeds as per Pharmacopoeia standards.
- FENFUROTM is dual action insulin sensitizer.
- In presence of high fiber Furostanolic Saponins, cells are more sensitive to insulin & an increase in number of insulin receptor sites occurs which are responsive to insulin to stimulate the cells ability to burn glucose ( i.e. newer insulin receptors with definite insulin sensitizing activity due to specific effects on the islets of langerhans in the pancreas).
- Furostanolic Saponins also increase peripheral utilization of insulin & insulin sensitizing activity. This brings down Hyperinsulinemia
- High fiber Furostanolic Saponins delays the rate of gastric emptying and slow carbohydrate absorption resulting in reducing insulin requirements.
- High fiber Furostanolic Saponins increases viscosity of the digesta thereby inhibiting cholesterol absorption from small intestine and also the inhibition of bile acid re-absorption from the terminal ileum. Thus lead to decrease in VLDL, LDL & Triglycerides levels.
- Patient should go for C-peptide test if it is very low, FENFURO can be added to existing medicinal regimen for three months regularly. After three months if any improvement is noticed in C-peptide level, patient can continue taking FENFURO otherwise FENFURO can be withdrawn.
- If C-peptide test is normal. Probably it is MODY (Maturity-onset diabetes of the young) case & FENFURO can help to regenerate newer insulin receptor sites & thereby insulin dosage can be reduced and diabetic complication can be controlled by reducing hyperinsulinemia.
Regular use of FENFURO as per prescribed dosage can help in reduction of HbA1c level thereby OHA/Insulin dosages can be reduced.
Extensive clinical evaluation at prestigious research institute viz. King George Medical University, Lucknow indicates safety and efficacy of the product in managing blood glucose levels.
FENFUROTM is a single ingredient phytochemical product derived from Fenugreek Seeds & product supported by both product & process patents. As the process involved is very unique, it makes FENFURO expensive as compared to other synthetic drugs.
- Those who are accustomed to being administered hormone and other steroidal drugs are vulnerable to Diabetes.
- Those who have swollen pancreas; in whose body the production of insulin ceases.
- Shortage of or defective, imperfect insulin produced by the body.
- Hereditary. Either parent suffering from Diabetes.
- When and if insulin produced by the body is not assimilated in the blood circulation.
- Unequal balance of insulin and glucose; excessive waste of insulin. Quantum of glucose in the body overweighing that of insulin.
- Stress, fear & tension.
- Wrong signals from the brain to the pancreas produces insufficient insulin.
- Mental fatigue.
- Melancholy and despair.
- Insomnia.
- Damage to skull and spine can cause diabetes.
- Those who consume alcoholic drinks, addiction to sweets, susceptibility during last stage of pregnancy and during lactation.
The risk factors for type 1 diabetes are unknown. Things that can put you at risk for type 2 diabetes include:
- Age — being older than 45.
- Overweight or obesity.
- Family history — having a mother, father, brother, or sister with diabetes.
- Having a baby with a birth weight more than 9 pounds.
- Having diabetes during pregnancy (gestational diabetes).
- High blood pressure — 140/90 mmHg or higher. Both numbers are important. If one or both numbers are usually high, you have high blood pressure.
- High cholesterol — total cholesterol over 240 mg/dL.
- Inactivity — exercising less than 3 times a week.
- Having a history of heart disease or stroke.
If you’re at least 45 years old, you should get tested for diabetes, and then you should be tested again every 3 years. If you’re 45 or older and overweight you may want to get tested more often. Ask your doctor for a fasting blood glucose test or an oral glucose tolerance test. Your doctor will tell you if you have normal blood glucose (blood sugar), pre-diabetes, or diabetes.
- Being very thirsty.
- Urinating a lot.
- Feeling very hungry.
- Feeling very tired.
- Losing weight without trying.
- Having sores that are slow to heal.
- Having dry or itchy skin.
- Losing feeling or having tingling in the hands or feet.
To help prevent type 2 diabetes and its complications, you should:
A- Choose carbs carefully.
B- Lose weight if you need to.
C- Get enough sleep.
D- Be active: exercise and diet.
E- Monitor blood sugar level daily.
F- Manage stress.
G- Say no to salt.
H- Break your smoking habit.
I- Pick super foods, don’t supersize.
J- Set up a doctor.
There is no cure for diabetes at this time, but there is a great deal of research going on in hopes of finding cures for both type 1 and type 2 diabetes. Many different approaches to curing diabetes are being studied, and researchers are making progress.